Ottawa-Shanghai Joint School of Medicine


ZHOU Liheng

Research Associate


Tel: 68385565

Research areas: breast disease

Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University

Member of Chinese Society of Clinical Oncology Youth Committee


Liheng Zhou obtained a master’s degree in Fudan University in 2008 and recieved a doctorate from Shanghai Jiaotong University in 2017. The main research direction is surgery-based comprehensive treatment of breast cancer, especially early breast cancer and locally advanced breast cancer. She published 20 SCI papers and many articles in Chinese core journal. She carried out the first minimally invasive surgery of breast diseases at Renji Hospital in Shanghai. She has given teaching and training for doctors specialized in breast disease in many provinces in China. She was awarded “Outstanding Individual Performance in Teaching” twice in Renji hospital in 2015 and 2017. She participated in and wrote two monographs of “Progression of China's clinical oncology" and "Diagnosis of breast disease".  She is in charging of a project of the Shanghai Municipal Health and Family Planning Commission, a cross-disciplinary project of Shanghai Jiaotong University, and a Learning and Research Practice Program for University Teachers funded by Shanghai Education Commission.


  1. Zhou, L., Y. Jiang, T. Yan, G. Di, Z. Shen, Z. Shao and J. Lu (2010). "The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures." Breast Cancer Res Treat 122(3): 795-801.

  2. Zhou, L., T. Yan, Y. Jiang, G. Di, Z. Shen, Z. Shao and J. Lu (2011). "Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: comparing aromatase inhibitors with tamoxifen." Breast 20(1): 15-20.

  3. Peng, J., L. Zhang, C. Yuan, L. Zhou, S. Xu, Y. Lin, J. Zhang, W. Yin and J. Lu (2017). "Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics." Cancer Manag Res 9: 891-901.

  4. Zhou, L., S. Xu, W. Yin, Y. Lin, Y. Du, Y. Jiang, Y. Wang, J. Zhang, Z. Wu and J. Lu (2017). "Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study." Oncotarget 8(45): 79305-79314.

  5. Du, Y., T. Yan, L. Zhou, W. Yin and J. Lu (2018). "A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer." Breast Cancer (Dove Med Press) 10: 201-206.

  6. Du, Y., L. Zhou, Y. Lin, K. Yin, W. Yin and J. Lu (2019). "Polymorphisms in microRNA let-7 binding sites of the HIF1AN and CLDN12 genes can predict pathologic complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer." Ann Transl Med 7(7): 138.

  7. Bayarmaa, B., Z. Wu, J. Peng, Y. Wang, S. Xu, T. Yan, W. Yin, J. Lu and L. Zhou (2019). "Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer." BMC Cancer 19(1): 877.

  8. Yuan, C., L. Zhou, L. Zhang, K. Yin, J. Peng, R. Sha, S. Zhang, Y. Xu, X. Sheng, Y. Wang, Y. Lin, S. Xu, W. Yin and J. Lu (2019). "Identification and integrated analysis of key differentially expressed circular RNAs in ER-positive subtype breast cancer." Epigenomics 11(3): 297-321.

  9. Peng, J., C. Yuan, Z. Wu, Y. Wang, W. Yin, Y. Lin, L. Zhou and J. Lu (2020). "Upregulation of microRNA1 inhibits proliferation and metastasis of breast cancer." Mol Med Rep 22(1): 454-464.

  10. Sheng, X., Y. Wang, F. Yang, Y. Lin, S. Xu, W. Yin, L. Zhou and J. Lu (2020). "Ultrasound-Guided Breast Biopsy: Improved Accuracy of 10-G Cable-Free Elite Compared With 14-G CCNB." J Surg Res 247: 172-179.